Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Angiotensin 2 as a Novel Treatment for Hepatorenal Syndrome

NCT04048707 is registered in ClinicalTrials.gov with University of California, Los Angeles as lead sponsor.

NCT NCT04048707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04048707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Angiotensin 2 as a Novel Treatment for Hepatorenal Syndrome
Lead sponsor
University of California, Los Angeles
Phase
Phase 2
Overall status
Withdrawn
Start date
July 1, 2021
Completion date
July 1, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, hepatorenal syndrome, kidney failure, acute